Companies › Madrigal Pharmaceuticals
1 active drug program in 8 registered trials: 3 Phase 3, 3 Phase 2, 1 Phase 4, 1 Phase 1; Cardiovascular, Gastroenterology, Infectious disease, Metabolic and endocrine; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Resmetirom Thyroid hormone receptor beta-1 agonist | THRB | Phase 4 | MASH - Metabolic Dysfunction-Associated Steatohepatitis; NASH; Non-Alcoholic Fatty Liver Disease; NASH - Nonalcoholic Steatohepatitis … | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05500222 | Resmetirom | Phase 3 | NASH | Gastroenterology | Dec 2026 |
| NCT04951219 | Resmetirom | Phase 3 | Non-Alcoholic Fatty Liver Disease | Metabolic and endocrine | Mar 2027 |
| NCT07143968 | Resmetirom | Phase 2 | MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease | Infectious disease | Oct 2027 |
| NCT07848191 | Resmetirom | Phase 4 | MASH - Metabolic Dysfunction-Associated Steatohepatitis | Metabolic and endocrine | Nov 2027 |
| NCT07830758 | Resmetirom | Phase 1 | MASH - Metabolic Dysfunction-Associated Steatohepatitis | Cardiovascular | Nov 2027 |
| NCT03900429 | Resmetirom | Phase 3 | NASH - Nonalcoholic Steatohepatitis | Gastroenterology | Jan 2028 |
| NCT07335601 | Resmetirom | Phase 2 | MASH - Metabolic Dysfunction-Associated Steatohepatitis | Metabolic and endocrine | Aug 2028 |
| NCT07763015 | Resmetirom | Phase 2 | MASH | Metabolic and endocrine | Jul 2029 |
Cash and short-term investments of $961m on 2026-09-30; operating cash outflow about $32m a year; runway about 365 months at that burn, to Feb 2057; 6 of 6 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 8 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Lexicon Pharmaceuticals Phathom Pharmaceuticals Guangdong Raynovent Biotech vTv Therapeutics Crystalys Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.